HK Stock MarketDetailed Quotes
09926 AKESO
- 72.050
- -1.050-1.44%
Trading Dec 2 11:30 CST
64.67BMarket Cap-80233P/E (TTM)
74.250High72.000Low3.48MVolume73.000Open73.100Pre Close253.45MTurnover0.39%Turnover Ratio28.89P/E (Static)897.56MShares78.75052wk High11.29P/B64.67BFloat Cap26.45052wk Low--Dividend TTM897.56MShs Float78.750Historical High--Dividend LFY3.08%Amplitude11.500Historical Low72.915Avg Price1000Lot Size--Div YieldTTM--Div Yield LFY
AKESO Stock Forum
Sign in to post a comment
$Summit Therapeutics (SMMT.US)$ fell nearly 20% Tuesday as the biotech firm's stock continued to give back part of a 280%+ rally that it saw last Thursday on positive study results for its candidate cancer drug ivonescimab.
SMMT sank to as low as $7.26 intraday, down 17.9% on the session and 35.5% from its $11.25 intraday peak last Thursday.
Summit had rallied 284% intraday last Thursday, rising to as high as $11.25...
SMMT sank to as low as $7.26 intraday, down 17.9% on the session and 35.5% from its $11.25 intraday peak last Thursday.
Summit had rallied 284% intraday last Thursday, rising to as high as $11.25...
3
2
Despite analysts downgrading revenue estimates and increasing loss per share forecasts for Akeso, the consensus price target remains steady. However, Akeso's revenues are expected to underperform the wider industry.
1
Akeso's weaker revenue outlook doesn't impact its P/S ratio as much as expected, posing a risk to investors. The share price may fall if low revenue growth affects sentiment. Investors should consider this risk before investing.
1
$Hang Seng Index (800000.HK)$ plunge deepened unceasingly after midday. It once stumbled 620 pts or 3.9% to bottom at 15,245, hitting an over-14-month low; last at 15,320, down 545 pts or 3.4%, with a total turnover of $88.5 billion.
Pharmaceuticals were sold off. $REMEGEN (09995.HK)$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B (02197.HK)$ nosedived 9.6% to $0.47, hitting record low. $VIVA BIOTECH (01873.HK)$ ...
Pharmaceuticals were sold off. $REMEGEN (09995.HK)$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B (02197.HK)$ nosedived 9.6% to $0.47, hitting record low. $VIVA BIOTECH (01873.HK)$ ...
1
Akeso's low P/S ratio indicates shareholder discomfort over its weak future revenue forecast. The market's gloomy sentiment about the company's growth prospects affects the low P/S ratio.
Akeso's strong net cash position and high liquidity suggest a low risk in its debt usage. The large conversion rate of EBIT to free cash flow also signals a positive financial health and potential profitability.
3
Key points:
1. Hang Seng Index fell 2.57% in the first two weeks (2023/05/22 to 2023/06/02), with all 12 Hang Seng industries falling. Among them, the Hang Seng healthcare sector fell 1.51%, outperforming the Hang Seng Index by 1.06 percentage points, ranking third among the 12 Hang Seng industries
2. On May 22, the results of the f...
1. Hang Seng Index fell 2.57% in the first two weeks (2023/05/22 to 2023/06/02), with all 12 Hang Seng industries falling. Among them, the Hang Seng healthcare sector fell 1.51%, outperforming the Hang Seng Index by 1.06 percentage points, ranking third among the 12 Hang Seng industries
2. On May 22, the results of the f...
$AKESO (09926.HK)$ Excellent clinical data, focus on product launch and data disclosure
Phase II clinical trial of AK112 combined with paclitaxel and chemotherapy in advanced non-small cell lung cancer
Objective sustained release rate (ORR) 53.8%, disease control rate (DCR) 100%, grade 3 or above treatment
The incidence of related adverse events was 13.5%. In combination with the PARP inhibitor olaparil for ovarian cancer
Phase Ib/II clinical, ORR/DCR 40.0%/86.7%. We expect it to be around 2024 on the market.
Phase II clinical trial of AK112 combined with paclitaxel and chemotherapy in advanced non-small cell lung cancer
Objective sustained release rate (ORR) 53.8%, disease control rate (DCR) 100%, grade 3 or above treatment
The incidence of related adverse events was 13.5%. In combination with the PARP inhibitor olaparil for ovarian cancer
Phase Ib/II clinical, ORR/DCR 40.0%/86.7%. We expect it to be around 2024 on the market.
1
No comment yet
Analysis
Price Target
No Data
Heat List
HK
Overall
Symbol
Latest Price
% Chg
No Data
MayFlower : It was predictable..
Midnite52 : yep